文献速递MDS 与骨髓增殖性肿瘤白血病

骨髓增生异常综合征与自身免疫性疾病:同一枚硬币的两面?

Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?
PubMed 文献 · Lancet Haematol · 2022-01-01

本文评述了骨髓增生异常综合征(MDS)与系统性炎症及自身免疫性疾病之间的关联,涵盖甲状腺疾病、中性粒细胞性皮肤病、多关节炎、结缔组织病、血管炎和自身免疫性血细胞减少等。文章认为MDS的病理生理与骨髓微环境过度炎症活动紧密相关,可能直接或通过刺激适应性免疫应答促进系统性炎症及自身免疫病,反之自身免疫病也可能促进克隆演化与骨髓生长紊乱而促发髓系恶性肿瘤。2020年首次报道的VEXAS综合征由影响髓系限制性细胞的突变所致,同时表现为骨髓增生异常和自身炎症,可能为这一生物学可能性提供线索。

要点

  • MDS与系统性炎症及自身免疫病之间的关联已被认识至少25年。
  • 自身免疫病或其治疗是MDS发生的危险因素,但MDS也可能诱发自身免疫病。
  • VEXAS综合征由影响髓系限制性细胞的突变所致,可同时表现为骨髓增生异常和自身炎症。

核心结论

  • MDS与系统性炎症及自身免疫病可能共享一种可表现为髓系肿瘤、自身炎症性疾病或两者的潜在疾病状态。

研究设计与样本

  • 本文为观点类综述,对MDS及相关疾病伴发的系统性炎症及自身免疫病的流行病学、病理生理和管理文献进行评述。

主要发现

  • MDS与自身免疫病的关联常包括甲状腺疾病、中性粒细胞性皮肤病、多关节炎、结缔组织病、血管炎和自身免疫性血细胞减少。
  • 自身免疫病或其治疗是MDS发生的危险因素,但MDS也可能诱发自身免疫病。
  • MDS的病理生理与骨髓微环境过度炎症活动紧密相关,可能直接或通过刺激适应性免疫应答促进系统性炎症及自身免疫病。
  • 自身免疫病可能促进克隆演化与骨髓生长紊乱,从而促进髓系恶性肿瘤的发生。
  • VEXAS综合征由影响髓系限制性细胞的突变所致,同时表现为骨髓增生异常和自身炎症。

临床怎么用

  • 系统性炎症及自身免疫病常依赖类固醇治疗;研究也评估了其他免疫调节疗法的作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator of autoimmune disease. Epidemiological studies examining disease risk in myelodysplastic syndromes with and without comorbid autoimmune illness have reached mixed conclusions. The pathophysiology of myelodysplastic syndromes is tightly linked to excessive inflammatory activity in the bone marrow microenvironment, which could promote systemic inflammatory and autoimmune diseases directly or by stimulation of the adaptive immune response. Alternatively, autoimmune diseases could promote clonal evolution and disordered bone marrow growth, promoting the development of myeloid malignancy. Additionally, therapy-related myeloid neoplasms-including myelodysplastic syndromes-have been diagnosed after treatment of autoimmune diseases with immunosuppressant therapies. These associations raise the following question: are myelodysplastic syndromes and systemic inflammatory and autoimmune diseases two sides of the same coin-that is, do they share an underlying disease state that can manifest as a myeloid neoplasm, an autoinflammatory illness, or both? VEXAS syndrome, which was first reported in 2020, is caused by a mutation that affects myeloid-restricted cells and manifests with both myelodysplasia and autoinflammation, and could give insight into this biological possibility. We note that systemic inflammatory and autoimmune diseases are often steroid-dependent; however, studies have also evaluated the roles of other immunomodulating therapies. In this Viewpoint, we critically appraise and review the literature on the epidemiology, pathophysiology, and management of systemic inflammatory and autoimmune diseases that are associated with myelodysplastic syndromes and related diseases.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Hochman MJ, DeZern AE. Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin? Lancet Haematol. 2022. PMID: 35772431. doi:10.1016/S2352-3026(22)00138-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。